Venetoclax

3:59
The challenges of post-MPN AML
Steven Knapper
2:41
R/R CLL: combination therapy and tailored treatment
Lydia Scarfò et al.
2:53
MURANO: outcomes after the end of treatment
John Seymour
2:41
Comparing CLL regimens with MRD
John Seymour
2:27
The MURANO study: key findings
John Seymour
3:11
Overcoming resistance to BTK inhibition in CLL
Jennifer Woyach
2:07
Real-world evidence of venetoclax vs ibrutinib vs idelalisib
Anthony Mato
1:11
Florence Cymbalista: iwCLL 2019, key points
Florence Cymbalista
1:27
Frontline therapies for treatment naive CLL patients
Danielle Brander
1:43
Predicting TLS in venetoclax-treated CLL patients
Anthony Mato
3:48
Predicting suboptimal response through intermediate MRD
Andrew Rawstron
5:46
MRD: standardization and application
Andrew Rawstron
4:14
Predicting resistance in CLL patients
Danielle Brander
1:53
MRD assessment in the era of novel therapies for CLL
Carol Moreno
3:45
MRD: a prognostic marker in targeted therapy
Talha Munir
2:35
MRD determinations in venetoclax treatment of CLL
Nicolas Martinez-Calle
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals